“…Recently, hallmarks of aging, including cellular senescence and stem cell exhaustion, were identified (Lopez‐Otin, Blasco, Partridge, Serrano, & Kroemer, 2013), guiding the research on aging and aging intervention strategies. Furthermore, the first clinical trial, Target Aging with Metformin (TAME), was approved to create a paradigm for evaluating pharmacologic approaches to delay aging (Barzilai, Crandall, Kritchevsky, & Espeland, 2016). The biguanide drug metformin, which is an FDA‐approved first‐line drug for treating type 2 diabetes mellitus, has been used clinically for over 60 years for its effectiveness, safety, and low cost (Bailey & Day, 2004); now, metformin is being considered as a promising geroprotector candidate.…”